These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 17397531)

  • 1. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies.
    Fournier C; Duverlie G; François C; Schnuriger A; Dedeurwaerder S; Brochot E; Capron D; Wychowski C; Thibault V; Castelain S
    Virol J; 2007 Mar; 4():35. PubMed ID: 17397531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.
    Bartosch B; Bukh J; Meunier JC; Granier C; Engle RE; Blackwelder WC; Emerson SU; Cosset FL; Purcell RH
    Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14199-204. PubMed ID: 14617769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection.
    Ansaldi F; Bruzzone B; Testino G; Bassetti M; Gasparini R; Crovari P; Icardi G
    J Viral Hepat; 2006 Jan; 13(1):5-10. PubMed ID: 16364076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus.
    Castelain S; Schnuriger A; François C; Nguyen-Khac E; Fournier C; Schmit JL; Capron D; Dubuisson J; Wychowski C; Thibault V; Duverlie G
    J Infect Dis; 2008 Aug; 198(3):332-5. PubMed ID: 18558868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a total hepatitis C virus (HCV) core antigen assay for the detection of antigenaemia in anti-HCV positive individuals.
    Valcavi P; Medici MC; Casula F; Arcangeletti MC; De Conto F; Pinardi F; Calderaro A; Chezzi C; Dettori G
    J Med Virol; 2004 Jul; 73(3):397-403. PubMed ID: 15170635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of antibodies to hepatitis C virus: false-negative results in an automated chemiluminescent microparticle immunoassay (ARCHITECT Anti-HCV) compared to a microparticle enzyme immunoassay (AxSYM HCV Version 3.0).
    Myrmel H; Navaratnam V; Asjø B
    J Clin Virol; 2005 Nov; 34(3):211-5; discussion 216-8. PubMed ID: 16112611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kuzuya T; Honda T; Hayashi K; Nakano I; Katano Y; Goto H
    Clin Infect Dis; 2005 Mar; 40(6):e49-54. PubMed ID: 15736006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection.
    Jensen TB; Gottwein JM; Scheel TK; Hoegh AM; Eugen-Olsen J; Bukh J
    J Infect Dis; 2008 Dec; 198(12):1756-65. PubMed ID: 19032070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TaqMan amplification system with an internal positive control for HCV RNA quantitation.
    Castelain S; Descamps V; Thibault V; François C; Bonte D; Morel V; Izopet J; Capron D; Zawadzki P; Duverlie G
    J Clin Virol; 2004 Nov; 31(3):227-34. PubMed ID: 15465417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the available anti-HCV antibody detection tests and RT-PCR assay in the diagnosis of hepatitis C virus infection.
    Tashkandy MA; Khodari YA; Ibrahim AM; Dhafar KO; Gazzaz ZJ; Azab BA
    Saudi J Kidney Dis Transpl; 2007 Nov; 18(4):523-31. PubMed ID: 17951937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic relevance of F protein in chronic hepatitis C virus infection.
    Komurian-Pradel F; Rajoharison A; Berland JL; Khouri V; Perret M; Van Roosmalen M; Pol S; Negro F; Paranhos-Baccalà G
    Hepatology; 2004 Oct; 40(4):900-9. PubMed ID: 15382175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.
    Burioni R; Mancini N; Carletti S; Perotti M; Grieco A; Canducci F; Varaldo PE; Clementi M
    Virology; 2004 Oct; 327(2):242-8. PubMed ID: 15351212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the patients with low levels of anti-HCV positivity].
    Zer Y; Karaoğlan I; Ciçek H; Karağoz ID; Sağlam M
    Mikrobiyol Bul; 2009 Jan; 43(1):133-9. PubMed ID: 19334390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2).
    Hadlock KG; Gish R; Rowe J; Rajyaguru SS; Newsom M; Warford A; Foung SK
    J Med Virol; 2001 Sep; 65(1):23-9. PubMed ID: 11505439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early detection of hepatitis C virus infection using a new combined antigen-antibody detection assay: potential use in HIV co-infected individuals].
    Schnuriger A; Dominguez S; Valantin MA; Tubiana R; Duvivier C; Ghosn J; Simon A; Katlama C; Thibault V
    Pathol Biol (Paris); 2006 Dec; 54(10):578-86. PubMed ID: 17030457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp).
    Berger A; Giroglou T; Leutz A; Ogbomo H; Pfaff K; Teuber G; Cinatl J; van Laer D; Doerr HW
    J Clin Virol; 2009 Sep; 46(1):55-60. PubMed ID: 19560398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus infection in dialysis and chronic liver patients: Viraemia dependent anti-E2-antibody response.
    Hanuka N; Sikuler E; Tovbin D; Neville L; Nussbaum O; Mostoslavsky M; Orgel M; Yaari A; Manor S; Dagan S; Hilzenrat N; Shemer-Avni Y
    J Med Virol; 2004 Aug; 73(4):529-35. PubMed ID: 15221896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of two hepatitis C virus typing assays in a Tunisian population].
    Ben Moussa M; Barguellil F; Bouziani A; Amor A
    Ann Biol Clin (Paris); 2003; 61(2):234-8. PubMed ID: 12702482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.
    Grollo L; Torresi J; Drummer H; Zeng W; Williamson N; Jackson DC
    Antivir Ther; 2006; 11(8):1005-14. PubMed ID: 17302370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and evaluation of a competitive ELISA for estimation of rabies neutralizing antibodies after post-exposure rabies vaccination in humans.
    Muhamuda K; Madhusudana SN; Ravi V
    Int J Infect Dis; 2007 Sep; 11(5):441-5. PubMed ID: 17321182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.